%0 Journal Article
%A Stocker, Hannah
%A Beyer, Léon
%A Perna, Laura
%A Rujescu, Dan
%A Holleczek, Bernd
%A Beyreuther, Konrad
%A Stockmann, Julia
%A Schöttker, Ben
%A Gerwert, Klaus
%A Brenner, Hermann
%T Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
%J Alzheimer's and dementia
%V 19
%N 1
%@ 1552-5260
%C Hoboken, NJ
%I Wiley
%M DKFZ-2022-00406
%P 23
%D 2023
%Z #EA:C070#LA:C070# / 2023 Jan;19(1):25-35
%X Blood biomarkers for Alzheimer's disease (AD) are the future of AD risk assessment. The aim of this study was to determine the association between plasma-measured phosphorylated tau (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) levels and risk of clinical AD incidence with consideration to the impact of cardiovascular health.Within a community-based cohort, biomarker levels were measured at baseline using single molecule array technology in 768 participants (aged 50-75) followed over 17 years. Associations among biomarkers and AD, vascular dementia, and mixed dementia incidence were assessed.GFAP was associated with clinical AD incidence even more than a decade before diagnosis (9-17 years), while p-tau181 and NfL were associated with more intermediate AD risk (within 9 years). Significant interaction was detected between cardiovascular health and p-tau181/NfL.GFAP may be an early AD biomarker increasing before p-tau181 and NfL and the effect modifying role of cardiovascular health should be considered in biomarker risk stratification.
%K Alzheimer's disease (Other)
%K blood biomarkers (Other)
%K cardiovascular risk (Other)
%K risk stratification (Other)
%K vascular dementia (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35234335
%R 10.1002/alz.12614
%U https://inrepo02.dkfz.de/record/179024